# Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)

> **NCT01569152** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 82 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** MK-8457 100 mg
- **DRUG:** Dose-Matched Placebo
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT01569152
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05-22
- **Primary completion:** 2013-10-03
- **Final completion:** 2013-10-03
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01569152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01569152, "Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01569152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*